$ALDX
Aldeyra Therapeutics, Inc.

2019 Q3 Form 10-Q Financial Statement

#000156459019041846 Filed on November 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2018 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.840M $3.070M
YoY Change -7.49% 107.43%
% of Gross Profit
Research & Development $16.22M $7.881M
YoY Change 105.87% 122.66%
% of Gross Profit
Depreciation & Amortization $20.00K $20.00K
YoY Change 0.0% 100.0%
% of Gross Profit
Operating Expenses $16.22M $7.881M
YoY Change 105.87% 122.66%
Operating Profit -$19.02M -$10.95M
YoY Change 73.72% 118.27%
Interest Expense $29.15K $28.85K
YoY Change 1.07% 4.6%
% of Operating Profit
Other Income/Expense, Net $301.2K $134.2K
YoY Change 124.47% 361.49%
Pretax Income -$18.72M -$10.81M
YoY Change 73.09% 116.68%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$18.72M -$10.81M
YoY Change 73.09% 116.85%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$690.5K -$515.5K
COMMON SHARES
Basic Shares Outstanding 27.58M 20.97M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $76.17M $35.10M
YoY Change 117.01% -26.72%
Cash & Equivalents $51.60M $18.01M
Short-Term Investments $24.57M $17.10M
Other Short-Term Assets $800.0K $1.700M
YoY Change -52.94% 54.55%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $77.02M $36.85M
YoY Change 109.04% -24.89%
LONG-TERM ASSETS
Property, Plant & Equipment $172.5K $243.5K
YoY Change -29.17% 540.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change -100.0%
Total Long-Term Assets $420.6K $286.5K
YoY Change 46.83% 62.15%
TOTAL ASSETS
Total Short-Term Assets $77.02M $36.85M
Total Long-Term Assets $420.6K $286.5K
Total Assets $77.44M $37.13M
YoY Change 108.56% -24.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $572.4K $3.442M
YoY Change -83.37% 609.38%
Accrued Expenses $11.32M $3.746M
YoY Change 202.32% 148.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $465.3K
YoY Change 9.09%
Total Short-Term Liabilities $12.12M $7.654M
YoY Change 58.31% 216.37%
LONG-TERM LIABILITIES
Long-Term Debt $14.39M $882.8K
YoY Change 1529.59% -2.48%
Other Long-Term Liabilities $100.0K
YoY Change
Total Long-Term Liabilities $14.39M $882.8K
YoY Change 1529.59% -2.48%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.12M $7.654M
Total Long-Term Liabilities $14.39M $882.8K
Total Liabilities $26.56M $8.537M
YoY Change 211.15% 156.78%
SHAREHOLDERS EQUITY
Retained Earnings -$186.2M -$127.9M
YoY Change 45.58% 37.99%
Common Stock $237.1M $156.5M
YoY Change 51.48% 12.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $50.88M $28.60M
YoY Change
Total Liabilities & Shareholders Equity $77.44M $37.13M
YoY Change 108.56% -24.57%

Cashflow Statement

Concept 2019 Q3 2018 Q3
OPERATING ACTIVITIES
Net Income -$18.72M -$10.81M
YoY Change 73.09% 116.85%
Depreciation, Depletion And Amortization $20.00K $20.00K
YoY Change 0.0% 100.0%
Cash From Operating Activities -$8.320M -$7.690M
YoY Change 8.19% 63.62%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$50.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $5.670M $30.00K
YoY Change 18800.0% -100.83%
Cash From Investing Activities $5.670M -$20.00K
YoY Change -28450.0% -99.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.84M 1.120M
YoY Change 1225.0% -95.83%
NET CHANGE
Cash From Operating Activities -8.320M -7.690M
Cash From Investing Activities 5.670M -20.00K
Cash From Financing Activities 14.84M 1.120M
Net Change In Cash 12.19M -6.590M
YoY Change -284.98% -135.62%
FREE CASH FLOW
Cash From Operating Activities -$8.320M -$7.690M
Capital Expenditures $0.00 -$50.00K
Free Cash Flow -$8.320M -$7.640M
YoY Change 8.9% 62.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14386706
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
225136127
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
172470
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11324963
CY2019Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
237047752
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
849087
CY2019Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
24567074
CY2019Q3 us-gaap Assets Current
AssetsCurrent
77020364
CY2019Q3 us-gaap Assets
Assets
77440999
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
572363
CY2019Q3 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
26000000
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 aldx Cash And Money Market Funds
CashAndMoneyMarketFunds
25604203
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
235225
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity File Number
EntityFileNumber
001-36332
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-1968197
dei Entity Address Address Line1
EntityAddressAddressLine1
131 Hartwell Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 320
dei Entity Address City Or Town
EntityAddressCityOrTown
Lexington
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02421
dei City Area Code
CityAreaCode
(781)
dei Local Phone Number
LocalPhoneNumber
761-4904
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2018Q4 aldx Cash And Money Market Funds
CashAndMoneyMarketFunds
3357472
CY2018Q4 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
44000000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
46242220
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1169594
CY2018Q4 us-gaap Assets Current
AssetsCurrent
94769286
CY2018Q4 aldx Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
86644
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
248165
CY2018Q4 us-gaap Assets
Assets
95091155
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3051678
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5421498
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
58720
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.77
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.40
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20969913
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26928725
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20168633
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-7687
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2637
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
14990
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-7687
CY2018Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2637
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
14990
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18722701
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10815202
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47651218
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6133990
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
720964
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
194848
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
14990
CY2018Q4 us-gaap Liabilities
Liabilities
8473176
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
27152
CY2019Q3 us-gaap Liabilities
Liabilities
26561705
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
26244
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8473176
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12116279
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-48976181
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1309973
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
134169
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-138535168
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
86617979
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95091155
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26244435
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26244435
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7880822
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34737420
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21274032
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8940771
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7330142
us-gaap Operating Income Loss
OperatingIncomeLoss
-28604174
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
344113
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28260061
us-gaap Investment Income Interest
InvestmentIncomeInterest
1262378
us-gaap Investment Income Interest
InvestmentIncomeInterest
427361
us-gaap Interest Expense
InterestExpense
59766
us-gaap Interest Expense
InterestExpense
83248
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1202612
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
218953
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9224
aldx Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
6500602
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3065912
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10946734
CY2018Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
163015
CY2018Q3 us-gaap Interest Expense
InterestExpense
28846
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10812565
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-10812565
us-gaap Operating Income Loss
OperatingIncomeLoss
-50178793
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
330329
CY2019Q3 us-gaap Interest Expense
InterestExpense
29154
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27151775
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27151775
CY2019Q3 aldx Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
-47102
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2839319
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19016189
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
301175
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-18715014
us-gaap Net Income Loss
NetIncomeLoss
-47666208
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27111600
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
12635
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
12635
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28247426
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18715014
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
77440999
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16223972
us-gaap Net Income Loss
NetIncomeLoss
-28260061
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-186201376
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
50879294
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5766
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47357472
aldx Net Loss
NetLoss
-47666208
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
39601019
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3126920
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14028981
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
85573
CY2019Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
115688
CY2018Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
85573
CY2018Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2637
CY2018Q3 aldx Net Loss
NetLoss
-10812565
us-gaap Profit Loss
ProfitLoss
-28260061
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
6500602
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-1309973
us-gaap Share Based Compensation
ShareBasedCompensation
3126920
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
11608
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
82996
us-gaap Depreciation
Depreciation
48161
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
683566
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2441407
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1509571
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21888956
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
248382
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
21573832
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
27459000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5636786
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14194871
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
194849
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
85614
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
14450000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
123186
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
43000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15242627
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14237485
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4246731
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2014685
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47357472
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20023337
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51604203
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18008652
us-gaap Nature Of Operations
NatureOfOperations
<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">NATURE OF BUSINESS </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aldeyra Therapeutics, Inc., together with its wholly-owned subsidiaries <font style="font-size:8pt;"></font>(the Company or Aldeyra), a Delaware corporation, is developing next-generation medicines to improve the lives of patients with immune-mediated diseases. </p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s principal activities to date include raising capital and research and development activities. </p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions, including fair value estimates for investments that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. The Company&#8217;s management evaluates its estimates and assumptions on an ongoing basis. Management&#8217;s most significant estimates in the Company&#8217;s financial statements include, but are not limited to, estimates related to clinical trial accruals, estimates related to prepaid and accrued research and development costs, acquired in-process research and development (IPR&amp;D) expense, accounting for income taxes and related valuation allowance, and accounting for stock-based compensation. Although estimates and assumptions are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. </p>
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4529956
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3126919
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3383047
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5396176
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3784460
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5396176
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3784460
CY2019Q3 us-gaap Cash
Cash
6472575
CY2019Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
16136718
CY2019Q3 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
27556218
CY2019Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
53556218
CY2018Q4 us-gaap Cash
Cash
2127175
CY2018Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
1230297
CY2018Q4 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
46251444
CY2018Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
90251444
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51604203
CY2019Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2018Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1339892
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1172880
CY2019Q3 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
9374374
CY2018Q4 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3882313
CY2019Q3 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
610697
CY2018Q4 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
366305
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
3659776
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
5931718
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
6451006
CY2018Q4 us-gaap Long Term Debt
LongTermDebt
16042500
aldx Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
ten years
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1557809
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1273720
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1317819
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
30000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
131587
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4539279
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2596879
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.17
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.86
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.00
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.28
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.64
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.80
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M26D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y5M1D
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1881826
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1834416
CY2019Q3 us-gaap Share Price
SharePrice
5.27
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
277673
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
us-gaap Operating Lease Expense
OperatingLeaseExpense
159263
CY2019Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
53088
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
57275
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
237671
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
294946
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
17273
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0

Files In Submission

Name View Source Status
0001564590-19-041846-index-headers.html Edgar Link pending
0001564590-19-041846-index.html Edgar Link pending
0001564590-19-041846.txt Edgar Link pending
0001564590-19-041846-xbrl.zip Edgar Link pending
aldx-10q_20190930.htm Edgar Link pending
aldx-20190930.xml Edgar Link completed
aldx-20190930.xsd Edgar Link pending
aldx-20190930_cal.xml Edgar Link unprocessable
aldx-20190930_def.xml Edgar Link unprocessable
aldx-20190930_lab.xml Edgar Link unprocessable
aldx-20190930_pre.xml Edgar Link unprocessable
aldx-ex311_8.htm Edgar Link pending
aldx-ex312_6.htm Edgar Link pending
aldx-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending